Pharvaris B.V. Competitors

Pharvaris B.V. (NASDAQ:PHVS) and Seer (NASDAQ:SEER) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, profitability, earnings and risk.

Analyst Ratings

This is a summary of current ratings and price targets for Pharvaris B.V. and Seer, as provided by MarketBeat.

Pharvaris B.V. currently has a consensus target price of $47.50, suggesting a potential upside of 82.62%. Seer has a consensus target price of $68.00, suggesting a potential upside of 39.54%. Given Pharvaris B.V.'s stronger consensus rating and higher probable upside, analysts clearly believe Pharvaris B.V. is more favorable than Seer.

Profitability

This table compares Pharvaris B.V. and Seer's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Pharvaris B.V. and Seer's gross revenue, earnings per share and valuation.

Summary

Pharvaris B.V. beats Seer on 3 of the 3 factors compared between the two stocks.

Nuvation Bio (NYSE:NUVB) and Pharvaris B.V. (NASDAQ:PHVS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, dividends and analyst recommendations.

Profitability

This table compares Nuvation Bio and Pharvaris B.V.'s net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Nuvation Bio and Pharvaris B.V.'s top-line revenue, earnings per share and valuation.

Analyst Recommendations

This is a summary of recent ratings and price targets for Nuvation Bio and Pharvaris B.V., as provided by MarketBeat.com.

Nuvation Bio currently has a consensus price target of $17.40, suggesting a potential upside of 63.23%. Pharvaris B.V. has a consensus price target of $47.50, suggesting a potential upside of 82.62%. Given Pharvaris B.V.'s higher probable upside, analysts clearly believe Pharvaris B.V. is more favorable than Nuvation Bio.

Summary

Nuvation Bio beats Pharvaris B.V. on 2 of the 3 factors compared between the two stocks.

ImmunityBio (NASDAQ:IBRX) and Pharvaris B.V. (NASDAQ:PHVS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations and institutional ownership.

Analyst Ratings

This is a summary of recent ratings and target prices for ImmunityBio and Pharvaris B.V., as reported by MarketBeat.

ImmunityBio currently has a consensus price target of $25.00, indicating a potential upside of 53.56%. Pharvaris B.V. has a consensus price target of $47.50, indicating a potential upside of 82.62%. Given Pharvaris B.V.'s higher possible upside, analysts plainly believe Pharvaris B.V. is more favorable than ImmunityBio.

Profitability

This table compares ImmunityBio and Pharvaris B.V.'s net margins, return on equity and return on assets.

Valuation and Earnings

This table compares ImmunityBio and Pharvaris B.V.'s revenue, earnings per share and valuation.

Summary

Pharvaris B.V. beats ImmunityBio on 2 of the 3 factors compared between the two stocks.

Pharvaris B.V. (NASDAQ:PHVS) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, valuation and profitability.

Valuation & Earnings

This table compares Pharvaris B.V. and Immunocore's gross revenue, earnings per share and valuation.

Analyst Ratings

This is a summary of recent ratings and target prices for Pharvaris B.V. and Immunocore, as provided by MarketBeat.

Pharvaris B.V. presently has a consensus price target of $47.50, indicating a potential upside of 82.62%. Immunocore has a consensus price target of $54.3333, indicating a potential upside of 43.36%. Given Pharvaris B.V.'s stronger consensus rating and higher probable upside, analysts clearly believe Pharvaris B.V. is more favorable than Immunocore.

Profitability

This table compares Pharvaris B.V. and Immunocore's net margins, return on equity and return on assets.

Summary

Pharvaris B.V. beats Immunocore on 3 of the 3 factors compared between the two stocks.

Pharvaris B.V. (NASDAQ:PHVS) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.

Valuation & Earnings

This table compares Pharvaris B.V. and BioAtla's revenue, earnings per share (EPS) and valuation.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Pharvaris B.V. and BioAtla, as provided by MarketBeat.

Pharvaris B.V. presently has a consensus price target of $47.50, indicating a potential upside of 82.62%. BioAtla has a consensus price target of $58.00, indicating a potential upside of 23.72%. Given Pharvaris B.V.'s higher possible upside, analysts clearly believe Pharvaris B.V. is more favorable than BioAtla.

Profitability

This table compares Pharvaris B.V. and BioAtla's net margins, return on equity and return on assets.

Summary

BioAtla beats Pharvaris B.V. on 2 of the 3 factors compared between the two stocks.

Pharvaris B.V. (NASDAQ:PHVS) and Cullinan Oncology (NASDAQ:CGEM) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, risk, earnings, analyst recommendations and profitability.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Pharvaris B.V. and Cullinan Oncology, as provided by MarketBeat.com.

Pharvaris B.V. currently has a consensus price target of $47.50, suggesting a potential upside of 82.62%. Cullinan Oncology has a consensus price target of $48.75, suggesting a potential upside of 51.16%. Given Pharvaris B.V.'s higher probable upside, research analysts clearly believe Pharvaris B.V. is more favorable than Cullinan Oncology.

Valuation and Earnings

This table compares Pharvaris B.V. and Cullinan Oncology's gross revenue, earnings per share and valuation.

Profitability

This table compares Pharvaris B.V. and Cullinan Oncology's net margins, return on equity and return on assets.

Summary

Pharvaris B.V. beats Cullinan Oncology on 1 of the 1 factors compared between the two stocks.